Localized
Advertisement
Dr. Sanchez-Salas comments on whether PSMA PET is useful for determining optimal candidates for focal therapy.
Dr. Sanchez-Salas details strategies for selecting between focal therapy versus active surveillance or definitive treatments.
Dr. Kaouk presented on the benefits of surgery for managing biochemically recurrent prostate cancer post-radiation.
Dr. Thompson, Jr. highlights his recently published large dataset of long-term complications of prostate cancer treatment.
Drs. Saji and Lebastchi explore focal therapy, covering its historical evolution, techniques, and energy modalities.
Dr. Ghazi is recognized as a pioneer in patient-specific surgical simulation, using state-of-the-art techniques in surgery.
Drs. Saji and Lebastchi provide an in-depth overview of focal therapy for prostate cancer, including HIFU and IRE therapies.
GETUG 14 recruited patients with both intermediate- and high-risk PCa, randomizing them to receive RT or stADT plus RT.
Dr. Greenstein shares insights on the overall survival benefit of apalutamide over enzalutamide in a recent real-world study.
Patients were guided through a VR experience to view their specific anatomy in a 3-dimensional space.
Data show that of patients with prostate cancer, Black men face higher incidence and mortality rates than White men.
For the treatment of localized prostate cancer, guidelines typically recommend the addition of ADT to RT in certain patients.
Drs. Stifelman and Ambinder discuss the novel approaches and adoption challenges of single-port and Da Vinci 5 systems.
Dr. Shore discusses treatment-related adverse events associated with apalutamide and ADT.
Dr. Shore discusses the effects of apalutamide plus ADT in patients with prostate cancer.
Drs. Joshua and Wallis contextualize the Metformin Active Surveillance Trial for management of low-risk prostate cancer.
New research provides evidence of 18F-rhPSMA-7 leading to more favorable disease outcomes for patients with BCR after RP.
The MAST trial evaluated metformin’s effects on reducing progression of low-risk prostate cancer during active ...
Researchers attempted to confirm whether treatment suspension for EMBARK patients may lead to improvements in HRQOL.
Prostate cancer is the 2nd most diagnosed cancer among men worldwide, but the disease lacks established re-treatment options.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.